GYKI-52895

Drugbox
IUPAC_name = 4-(8,9-Dihydro-8-methyl-7H-1,3-dioxolo [4,5-h] [2,3] benzodiazepin-5-yl)benzenamine


width=180
CAS_number=869360-93-0
ATC_prefix=
ATC_suffix=
ATC_supplemental=
PubChem=3539
DrugBank=
C=17 | H=17 | N=3 | O=2
molecular_weight = 295.34
bioavailability=
metabolism =
elimination_half-life=
excretion =
pregnancy_category =
legal_status =
routes_of_administration=

GYKI-52895 is a drug which is a 2,3-benzodiazepine derivative. Unlike other similar drugs, GYKI-52895 is a selective dopamine reuptake inhibitor, [Horváth K, Szabó H, Pátfalusi M, Berzsenyi P, Andrási F. Pharmacological Effects of GYKI 52895, a New Selective Dopamine Uptake Inhibitor. "European Journal of Pharmacology". 1990; 183(4):1416-1417.] [Huang CL, Chen HC, Huang NK, Yang DM, Kao LS, Chen JC, Lai HL, Chern Y. Modulation of Dopamine Transporter Activity by Nicotinic Acetylcholine Receptors and Membrane Depolarization in Rat Pheochromocytoma PC12 Cells. "Journal of Neurochemistry". 1999; 72(6): 2437–2444.] which presumably would produce stimulant effects "in vivo".

References

[http://www.google.com/patents?id=SfgNAAAAEBAJ&dq=6638928 US Patent 6638928]